Osmotica Pharmaceuticals plc (OSMT)’s Financial Results Comparing With Edge Therapeutics Inc. (NASDAQ:EDGE)

As Biotechnology companies, Osmotica Pharmaceuticals plc (NASDAQ:OSMT) and Edge Therapeutics Inc. (NASDAQ:EDGE) are our subject to contrast. And more specifically their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Osmotica Pharmaceuticals plc 274.34M 1.50 6.40M -0.13 0.00
Edge Therapeutics Inc. N/A 0.00 51.69M -2.09 0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.


Table 2 provides us Osmotica Pharmaceuticals plc and Edge Therapeutics Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Osmotica Pharmaceuticals plc -2.33% 0% 0%
Edge Therapeutics Inc. 0.00% -120.9% -81.4%


The Current Ratio of Osmotica Pharmaceuticals plc is 1.3 while its Quick Ratio stands at 1.1. The Current Ratio of rival Edge Therapeutics Inc. is 5.5 and its Quick Ratio is has 5.5. Edge Therapeutics Inc. is better equipped to clear short and long-term obligations than Osmotica Pharmaceuticals plc.

Insider and Institutional Ownership

The shares of both Osmotica Pharmaceuticals plc and Edge Therapeutics Inc. are owned by institutional investors at 37% and 31.9% respectively. Insiders owned 41.8% of Osmotica Pharmaceuticals plc shares. On the other hand, insiders owned about 14.97% of Edge Therapeutics Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Osmotica Pharmaceuticals plc -0.38% -11% 0% 0% 0% -3.68%
Edge Therapeutics Inc. -31.11% -33.09% -45.09% -51.77% -94.96% -95.04%

For the past year Osmotica Pharmaceuticals plc’s stock price has smaller decline than Edge Therapeutics Inc.


Osmotica Pharmaceuticals plc beats on 7 of the 9 factors Edge Therapeutics Inc.

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER to treat Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone to treat muscle spasms; and ConZip for pain, as well as women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. Its non-promoted approved products comprise Methylphenidate ER for ADHD; Venlafaxine ER tablets for major depressive disorder and social anxiety disorder; Hydromorphone ER for pain; Nifedipine ER for hypertension; Sodium Benzoate/Sodium Phenylacetate for hyperammonemia; Oxybutynin ER for overactive bladder; and prescription prenatal vitamins for nutritional requirements during pregnancy. The company's products under development include Ontinua ER, which is in Phase III clinical trials to treat multiple sclerosis spasticity, and Phase I clinical trials to treat opioid and alcohol use disorders; RVL-1201, which is in Phase III clinical trials to treat Blepharoptosis; and Osmodex and other ANDAs for various indications. Osmotica Pharmaceuticals plc is based in Bridgewater, New Jersey.

Edge Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and seeks to commercialize hospital-based therapies for acute life-threatening neurological and other conditions. Its lead product includes EG-1962, a polymer-based microsphere used for the treatment of aneurysmal subarachnoid hemorrhage. The company is also developing EG-1964 for the management of chronic subdural hematoma as a prophylactic treatment to prevent recurrent bleeding on the surface of the brain. Edge Therapeutics, Inc. was founded in 2009 and is headquartered in Berkeley Heights, New Jersey.


Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.